Comparative Pharmacology
Head-to-head clinical analysis: SODIUM TETRADECYL SULFATE versus STERITALC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM TETRADECYL SULFATE versus STERITALC.
SODIUM TETRADECYL SULFATE vs STERITALC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium tetradecyl sulfate is a synthetic anionic surfactant that acts as a sclerosing agent. It works by causing endothelial damage and inflammation of the venous wall, leading to fibrosis and occlusion of the injected vein.
Sterile talc (STERITALC) induces pleural inflammation and fibrosis, leading to adhesion of the pleural layers. This mechanism is mediated by activation of mesothelial cells and fibroblasts, resulting in release of inflammatory cytokines and growth factors.
1% to 3% solution, 0.1-0.5 mL per injection, intravenous, as needed for sclerotherapy; maximum 10 mL per session.
Sterile talc powder for intrapleural administration: 4-8 g mixed with 50-250 mL normal saline, instilled via chest tube for pleurodesis. Single dose typically used.
None Documented
None Documented
Approximately 2.5 hours (range 1.5–4 hours) in patients with normal renal function. Clinical context: prolonged in renal impairment, requiring dose adjustment.
Not applicable; talc particles are not metabolized and remain in the pleural space indefinitely, with gradual clearance over months to years via macrophage uptake and lymphatic drainage.
Primarily renal; approximately 95% of the dose is excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination (<5%).
Sterile talc (STERITALC) is not absorbed systemically following intrapleural administration. Excretion occurs locally via phagocytosis and clearance by pleural lymphatics; no significant renal, biliary, or fecal elimination applies.
Category C
Category C
Sclerosing Agent
Sclerosing Agent